The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.
Publication/Presentation Date
1-1-2017
Abstract
BACKGROUND: Multiple sclerosis (MS) diagnostic criteria have changed since the ORACLE-MS study was conducted; 223 of 616 patients (36.2%) would have met the diagnosis of MS vs clinically isolated syndrome (CIS) using the newer criteria.
OBJECTIVE: The objective of this paper is to assess the effect of cladribine tablets in patients with a first clinical demyelinating attack fulfilling newer criteria (McDonald 2010) for MS vs CIS.
METHODS: A post hoc analysis for subgroups of patients retrospectively classified as fulfilling or not fulfilling newer criteria at the first clinical demyelinating attack was conducted.
RESULTS: Cladribine tablets 3.5 mg/kg (
CONCLUSIONS: Regardless of the criteria used to define CIS or MS, 3.5 mg/kg cladribine tablets are effective in patients with a first clinical demyelinating attack.
Volume
3
Issue
4
First Page
2055217317732802
Last Page
2055217317732802
ISSN
2055-2173
Published In/Presented At
Freedman, M. S., Leist, T. P., Comi, G., Cree, B. A., Coyle, P. K., Hartung, H. P., Vermersch, P., Damian, D., & Dangond, F. (2017). The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Multiple sclerosis journal - experimental, translational and clinical, 3(4), 2055217317732802. https://doi.org/10.1177/2055217317732802
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
29051829
Department(s)
Administration and Leadership
Document Type
Article